Point-of-care molecular diagnostics

01Overview and value chain

Markers: [EC: IVDR 2017/746 | OECD: Biotech-health | Regulator: FDA (USA), EMA (European Union), NMPA (China)]

Point-of-care molecular diagnostics run PCR-grade nucleic-acid testing outside a central laboratory — in a clinic, emergency department, field site or resource-limited setting — returning a result in minutes to an hour instead of the day or more a send-out lab test requires. Cepheid’s GeneXpert cartridge-based system (owned by Danaher) recently received FDA clearance and EU IVDR CE marking for its Xpert GI gastrointestinal-pathogen panel, delivered Xpert Hemorrhagic Fever Panel tests to Africa during an Ebola Bundibugyo outbreak response, and expanded its sequencing partnership with Oxford Nanopore. Abbott’s ID NOW isothermal amplification platform is a widely deployed rapid molecular test, evaluated in published studies against central-lab RT-PCR and covered by multiple FDA 510(k) clearances for expanded panels. bioMérieux’s BIOFIRE FilmArray syndromic testing system runs multiplex PCR panels for respiratory and gastrointestinal pathogens, with a 2026 510(k) submission updating its GI panel line. In China, Sansure Biotech has scaled domestic point-of-care molecular testing manufacturing and distribution as a STAR Market-listed IVD company. In India, Molbio Diagnostics’ Truenat chip-based real-time PCR platform is WHO-endorsed for tuberculosis testing and now exports to more than 85 countries, serving as a reference point-of-care platform for resource-limited settings globally.

The key directions of point-of-care molecular diagnostics are:

1. Cartridge-based PCR platforms (Cartridge-Based PCR): self-contained, sample-to-answer PCR cartridges requiring minimal operator training — Cepheid GeneXpert, bioMérieux BIOFIRE FilmArray.
2. Isothermal amplification testing (Isothermal Amplification): rapid nucleic-acid amplification at a constant temperature, avoiding the thermal-cycling hardware a conventional PCR instrument requires — Abbott ID NOW.
3. Chip-based rapid PCR for resource-limited settings (Chip-Based Rapid PCR): battery-powered, portable chip-based real-time PCR designed for field and low-infrastructure deployment — Molbio Diagnostics’ Truenat.
4. Domestic point-of-care testing scale-up (Point-of-Care Testing Scale-Up): national manufacturing and distribution capacity for point-of-care molecular platforms built out during pandemic-era demand — Sansure Biotech.

Sectoral value chain

[cartridge/chip/reagent design] ──> [instrument manufacturing] ──> [regulatory clearance (FDA/IVDR/NMPA)]
                                                    │
                                       (point-of-care deployment: clinic/field/hospital)
                                                    │
                                                    ▼
[result reporting & clinical action] <─── [sample-to-answer testing] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• Cartridge-based nucleic-acid testing (Cartridge-Based PCR): self-contained cartridges integrate sample prep, amplification and detection into one disposable unit, removing the need for a trained lab technician.
• Isothermal amplification chemistry (Isothermal Amplification): amplification methods that run at a single constant temperature simplify the instrument to a low-cost heater/reader rather than a thermal cycler.
• Portable chip-based real-time PCR (Chip-Based Rapid PCR): battery-powered, ruggedized chip platforms extend PCR-grade testing to settings without reliable power or lab infrastructure.

02US

The US anchors the largest point-of-care molecular diagnostics platform companies, spanning cartridge-based PCR and isothermal amplification technology.

GeneXpert, ID NOW, FDA

• Cepheid (Danaher): its GeneXpert cartridge-based system recently received FDA clearance and EU IVDR CE marking for the Xpert GI gastrointestinal-pathogen panel, delivered Xpert Hemorrhagic Fever Panel tests to Africa during an Ebola Bundibugyo outbreak, and expanded its sequencing partnership with Oxford Nanopore Technologies.
• Abbott: its ID NOW isothermal amplification platform is a widely deployed rapid point-of-care molecular test, evaluated against central-lab RT-PCR in published studies and covered by multiple FDA 510(k) clearances for panel updates.
• FDA framework: point-of-care molecular platforms clear the FDA via 510(k) submissions and CLIA-waiver classification for near-patient use outside a certified laboratory, with new panel clearances issued regularly as pathogen coverage expands.

03CN

China has scaled a large domestic point-of-care molecular testing manufacturing and distribution base, led by Sansure Biotech.

Sansure Biotech, NMPA

• Sansure Biotech (圣湘生物): a STAR Market-listed Chinese in-vitro diagnostics company that scaled domestic point-of-care molecular testing manufacturing and distribution capacity, continuing as a leading domestic IVD platform provider.
• NMPA framework: point-of-care molecular diagnostic devices and reagent kits register with NMPA as in-vitro diagnostic products, with domestic manufacturers competing alongside imported cartridge-based and isothermal platforms.

04EU

France anchors Europe’s point-of-care molecular diagnostics tier through bioMérieux’s syndromic testing platform.

BIOFIRE FilmArray, IVDR

• bioMérieux: its BIOFIRE FilmArray system runs multiplex syndromic PCR panels for respiratory and gastrointestinal pathogens, with a 2026 510(k) submission updating its gastrointestinal panel line to expand pathogen detection.
• IVDR framework: point-of-care molecular diagnostic devices sold in the EU require conformity assessment and CE marking under the In Vitro Diagnostic Regulation (IVDR 2017/746), the same framework Cepheid’s Xpert GI panel cleared.

05Leading companies and research institutes

06Tech stack and innovations

The stack integrates sample preparation, nucleic-acid amplification and detection into a single self-contained consumable, paired with a simplified instrument that removes the need for a trained lab technician or central-lab turnaround time.

1. Cartridge-based sample-to-answer PCR (Cartridge-Based PCR):
   • Cepheid’s GeneXpert and bioMérieux’s BIOFIRE FilmArray integrate sample prep, PCR amplification and detection into a disposable cartridge, delivering a lab-grade multi-pathogen result without a trained operator.
2. Isothermal amplification (Isothermal Amplification):
   • Abbott’s ID NOW runs nucleic-acid amplification at a single constant temperature, simplifying the instrument to a compact, low-cost reader rather than a thermal cycler.
3. Chip-based portable real-time PCR (Chip-Based Rapid PCR):
   • Molbio Diagnostics’ Truenat platform runs battery-powered, chip-based real-time PCR validated by the WHO for tuberculosis testing, extending PCR-grade diagnostics to settings without reliable power or lab infrastructure.
4. National POCT manufacturing scale (Point-of-Care Testing Scale-Up):
   • Sansure Biotech’s domestic manufacturing and distribution capacity, built out during pandemic-era demand, continues to supply China’s point-of-care molecular testing market at scale.

07Value chains and production pipelines

Industrial pipeline of a point-of-care molecular diagnostic (FDA 510(k)/CLIA-waiver / EU IVDR 2017/746)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Cartridge/chip/reagent │ ───> │ 2. Instrument             │
│    design                  │      │    manufacturing            │
└───────────────────────────┘      └───────────────────────────┘
                                                   │
                                                   ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Point-of-care          │ <─── │ 3. Regulatory clearance   │
│    deployment               │      │                           │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Sample-to-answer       │ ───> │ 6. Result reporting &    │
│    testing                 │      │    clinical action          │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Cartridge, chip or reagent design

The self-contained reaction chemistry — cartridge-based PCR (GeneXpert, BIOFIRE), isothermal amplification (ID NOW) or chip-based real-time PCR (Truenat) — is engineered for the target pathogen panel and consumable format.

Stage 2: Instrument manufacturing

The benchtop reader or portable instrument that runs the cartridge, chip or reagent cassette is manufactured, ranging from hospital-benchtop systems to Molbio’s battery-powered field-deployable devices.

Stage 3: Regulatory clearance

The platform and each pathogen panel clear FDA 510(k)/CLIA-waiver review, EU IVDR CE marking, or NMPA registration, with clearances issued panel-by-panel as pathogen coverage expands (Cepheid’s Xpert GI, bioMérieux’s updated GI panels).

Stage 4: Point-of-care deployment

The cleared instrument is placed at the point of need — a hospital emergency department, outpatient clinic, or resource-limited field site — rather than a centralized reference laboratory.

Stage 5: Sample-to-answer testing

An operator loads the patient sample directly into the cartridge or chip; the instrument runs sample preparation, amplification and detection automatically, returning a result in minutes to roughly an hour.

Stage 6: Result reporting and clinical action

The result feeds an immediate treatment decision (appropriate antibiotic/antiviral selection, isolation precautions) or, in outbreak settings like Cepheid’s hemorrhagic-fever panel deployment in Africa, a public health response action.